Έμβλημα Κυπριακής Δημοκρατίας

News


Notification of concentration regarding the acquisition of the sharecapital of Biosynth Beteiligungs AG, Inc. by KKR & Co (via Kohlberg Kravis Roberts & Co. LP and Gallus Bidco Limited) and Dr. Urs Spitz
06/12/2021


The Service of the Commission for the Protection of Competition has received a notification of a concentration, according to Section 10 of the Control of Concentrations between Enterprises Law of 2014, concerning the acquisition of the sharecapital of Clearhaus A/S, 3dsecure.io ApS και QuickPay ApS by Unzer Group GmbH.

Gallus Bidco Limited is a company duly registered under the laws of United Kingdom. This company is a special purpose vehicle, without previous business activities, which was established for the purposes of this transaction. Gallus Bidco Limited is controlled indirectly by KKR & Co. Inc.

KKR & Co. Inc. is listed on the New York Stock Exchange and is an international investment firm that offers a wide range of alternative investment funds and other investment products to investors. KKR & Co. Inc. also provides capital market solutions for the company, its affiliated portfolio companies and other clients.

Dr. Urs Spitz is the founder of Biosynth Beteiligungs AG, Inc. and currently the CEO and President of Biosynth Beteiligungs AG, Inc..
The Target of this concentration is Biosynth Beteiligungs AG, Inc. which is a company duly registered under the laws of Switzerland, and it is a manufacturer of organic fine chemicals in the field of enzyme substrates, indole derivatives and special chemicals for microbiology, molecular biology, diagnostics, pharmaceutical industry, chemical industry and for food and environmental testing. The Target consists of two sections: the research products section and the pharmaceuticals and diagnostics section.







  Twitter Icon  Facebook Icon

Cartel Hotline

Commission Decisions

whistleblowers

e-procurement

GDPR

About Cyprus

Your Europe